Overviewing the Role of Amyloid-ß Oligomers and Valiltramiprosate in Alzheimer Disease: John Hey, PhD

WATCH TIME: 5 minutes | Captions are auto-generated and may contain errors.

"I presented new data from our phase 3 APOLLOE4 trial. I focused on clinical outcomes in early Alzheimer, especially in the pre-specified mild cognitive impairment population. We’re seeing meaningful effects on disease progression and neuroprotection in this group, which we think is critical for targeting disease before major cognitive decline sets in."

Valiltramiprosate (Alzheon), an oral agent designed to inhibit amyloid oligomer formation, was assessed in the phase 3 APOLLOE4 trial (NCT04693520) in patients with early Alzheimer disease (AD) who were APOE4 homozygotes. The phase 3 study randomized 325 participants to receive either placebo or 265 mg twice daily, stratified by mild cognitive impairment (MCI) or mild AD. Although the trial did not meet its primary end point, treatment with valiltramiprosate showed a significant slowing of hippocampal atrophy. Primary and secondary clinical outcomes of the trial included Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Clinical Dementia Rating – Sum of Boxes (CDR-SB), and the Disability Assessment for Dementia (DAD).^1,2

In the prespecified MCI subgroup (n = 125), valiltramiprosate showed nominally significant benefits on ADAS-Cog13 and DAD, a trend toward improvement on CDR-SB, and robust reductions in atrophy across hippocampal volume (HV; 6%), cortical thickness (CT; 35%), and whole brain volume (WBV; 22%) compared with placebo. Structural preservation correlated strongly with clinical outcomes, including significant associations between HV, CT, and WBV changes and measures of cognition, function, and global status. Overall, the study authors believe these findings support the potential efficacy of valiltramiprosate at the MCI stage, aligning with its proposed mechanism of preventing amyloid oligomer formation to protect against synaptic dysfunction and neurodegeneration.

At the recently concluded 2025 Alzheimer’s Association International Conference, held July 27-30, in Toronto, Canada, John Hey, PhD, chief scientific officer at Alzheon, presented these data from APOLLOE4 at a scientific symposium. In an interview with NeurologyLive^® at the conference, Hey provided an overview of the symposium, which was centered around the role of amyloid-ß oligomers in AD and the translational impact of targeting these toxic species. He noted that the discussion emphasized mechanistic insights into oligomer formation, preclinical validation, and clinical applications, including recent antibody therapies and valiltramiprosate.

Click here for more coverage of AAIC 2025.

REFERENCES
1. Abushakra S, Doraiswamy PM, Liang E, et al. Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre-Specified MCI Group: Subgroup Analysis from the 78-Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes. Presented at: 2025 Alzheimer’s Association International Conference; July 27-31; Toronto, Canada. Abstract 108827.
2. Cohen S, Gandy S, Ono K, Geerts H, Hey J. Inhibition of Beta Amyloid Oligomer Neurotoxicity with Oral Valiltramiprosate. Presented at: 2025 Alzheimer’s Association International Conference; July 27-31; Toronto, Canada.